Determinants of risk infection during therapy with anti TNF-alpha blocking agents in rheumatoid arthritis

Open Rheumatology Journal

Volumn 6, Issue 1, 2012, Pages 33-37

  Benucci, M ^a   Saviola, G ^b   Baiardi, P ^c   Manfredi, M ^d   Puttini, Piercarlo Sarzi ^e   Atzeni, Fabiola ^e,f  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d Laboratory of Immunology and Allergology Hospital S Giovanni di Dio   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Infections; Peripheral mononuclear cells; TNF blocking agents

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CELL POPULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFECTION RISK; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS;

EID: 84860677657     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901206010033     Document Type: Article

References (31)

1. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-2293.
2. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25: 1072-1077.
3. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745-756.
4. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-196.
5. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997; 66: 95-101.
6. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol 2003; 24: 254-258.
7. Alves-Rosa MF, Palermo MS, Isturiz MA. Enhancement of immune complex clearance by TNF-alpha in a murine model. Clin Immunol Immunopathol 1998; 89: 214-221.
8. Galloway GB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology(Oxford) 2010; 50(1): 124-131.
9. Zanoni I, Ostuni R, Capuano G, et al. CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature 2009; 460(7252): 264-268.
10. Eissner G, Kirchner S, Lindner H et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 2000; 164: 6193-6198.
11. Xin L, Wang J, Zhang H et al. Dual regulation of soluble tumor necrosis factor-a induced activation of human monocytic cells via modulating transmembrane TNF-a-mediated "reverse signaling". Int J Mol Med 2006; 18: 885-892.
12. Rossol M, Meusch U, Pierer M et al. Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J Immunol 2007; 179: 4239-4248.
13. Rigby WF. Drug insight: different mechanisms of action of tumor necrosis factor antagonists passive-aggressive behavior? Nat Clin Pract Rheumatol 2007; 3: 227-233.
14. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T Transmembrane TNF-a: structure, function and interaction with anti-TNF agents. Rheuamtology(Oxford) 2010; 49: 1215-1228
15. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-279.
16. Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13: 1323-1332.
17. Kaymakcalan Z, Sakorafas P, Bose S et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131: 308-316.
18. Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-TNF agents on transmembrane TNF-expressing cells: comparison among infliximab, etanercept and adalimumab. Arthritis Rheum 2008; 58: 1248-1257.
19. Arora T, Padaki R, Liu L et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009; 45: 124-131.
20. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-259.
21. Mitoma H, Horiuchi T, Hatta N et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-a. Gastroenterology 2005; 128: 376-392.
22. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev 2005; 204: 55-73
23. Hershman MJ, Cheadle WG, Wellhausen SR, et al. Monocyte HLA-DR antigen expression characterizes clinical outcome in trauma patient. Br J Surg 1990; 77: 204-207.
24. Cheadle WG, Hershman MJ, Wellhausen SR, Polk HC. HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am J Surg 1991; 161: 639-645.
25. Ziegler-Heitbrock HW, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunol Today 1993; 14: 121-125.
26. Haziot A, Ferrero E, Kontgen F, et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996; 4: 407-414.
27. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005; 34 (Suppl 1): 34-38.
28. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 138-144.
29. Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009; 8: 266-273.
30. Dixon WG, Watson K, Lunt K, Hyrich KL. British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DPM. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 2368-2376.
31. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-a antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306(21): 2331-2339.